drugset / Trial / NCT04899414
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
Phase 2
Unknown
50 enrolled
Peking University
Peking University Cancer Hospital & Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been well-defined. This phase II study aimed to evaluate the efficacy and safety of Dexamethasone, azacytidine, Pegaspargase, Tislelizumab (DAPT) regimen for patients with newly diagnosed advanced stage ENKTL , non-upper aerodigestive tract NK/T- cell lymphoma（NUAT- NKTCL）and relapsed refractory NK/T cell lymphoma.
Timeline
- Start
- 2021-05-18
- Primary completion
- 2023-05-18
- Completion
- 2023-10-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 100 mg | Intravenous |
| Subject | Dexamethasone | Small molecule | 40 mg | Intravenous |
| Subject | Pegaspargase | Protein / enzyme biologic | 3750 iu | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |